Brodalumab met primary endpoints, deaths called ‘unrelated’

The investigational interleukin-17 inhibitor brodalumab met both primary endpoints in a phase III, double-blind, placebo-controlled trial of 661 patients with moderate to severe plaque psoriasis,...

Source: Rheumatology News - March 7, 2016 Category: Rheumatology Source Type: research